IP50-19: Diuretic Effect Associated with Nadofaragene Firadenovec Instillation Therapy - Insight into Treatment Tolerability

IP50-19: Diuretic Effect Associated with Nadofaragene Firadenovec Instillation Therapy - Insight into Treatment Tolerability

Sunday, May 17, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)

146A

Abstract

Speakers

Clinical Research AssistantFox Chase - Temple Urologic Institute

Sessions

IP50: Bladder Cancer: Non-invasive IV

Sunday, May 17, 2026 7:00 AM to 9:00 AM

Christopher Anderson · Columbia University Medical Center

William Tabayoyong · Department of Urology

Mary Westerman · Department of Urology, University of North Carolina

Registered attendees

Alexander Kutikov

Alexander Kutikov

Chair, Urology and Urologic OncologyFox Chase Cancer Center

David Han

FellowFox Chase-Temple Urologic Institute

Scott Flanders

VP of Medical AffairsImmunityBio, Inc.

Log in

See all the content and easy-to-use features by logging in or registering!